As the top management of Huntingdon Life Sciences prepared for breakfast with top New York Stock Exchange officials last month to celebrate the launch of their US listing, they had not even poured the coffee before their plans were shattered.
The exchange decided to defer the quotation of the UK-based biomedical research company with just minutes to spare, in a move that still has not been fully explained but which seems almost certain to have been triggered by pressure from animal rights extremists.
